FindTrial
Sign In

Molecular detection as an companion diagnostics and prognostic marker of therapeutic efficacy of targeted/immunotherapy for pediatric soft tissue sarcoma

Molecular detection as an companion diagnostics and prognostic marker of therapeutic efficacy of targeted/immunotherapy for pediatric soft tissue sarcoma

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000037308
Enrollment
Unknown
Registered
2020-08-27
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pediatric soft tissue sarcoma

Interventions

case series:Nil

Sponsors

Xinhua Hospital, School of Medicine, Shanghai Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. The age of initial diagnosis is less than 12 years old; 2. The pathological type of the tumor was soft tissue sarcoma.

Exclusion criteria

Exclusion criteria: Nil

Design outcomes

Primary

MeasureTime frame
NGS high throughput total exon and transcriptome sequencing;—

Countries

China

Contacts

Public ContactLifeng Wang

Xinhua Hospital, School of Medicine, Shanghai Jiaotong University

wlf6009@163.com+86 15021779369

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026